Clinical trials: FAPI
Pleural Mesothelioma, Pleural Diseases
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
Seventy (N=70) patients with suspected pleural mesothelioma (PM) lesions referred to pleural biopsy will be recruited, and undergo an additional FAPI PET/CT at primary staging.
- Conditions
- Pleural Mesothelioma, Pleural Diseases, Cancer, FAPI
- Trial name
- FAPI-PM (NCT06790082)
- Testing
- [68Ga]Ga-FAPI-46 PET/CT
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- Aalborg University Hospital
Cancer
The Therapeutic Efficacy of 18F-FDG Combined With 18F-FAPI PET/MR in Neoadjuvant Therapy for Gastric Cancer
Gastric cancer is the fifth most common cancer worldwide and the third leading cause of cancer-related deaths. Although surgical treatment can benefit the survival of the vast majority of patients, currently only early gastric…
- Trial name
- NCT06327386
- Testing
- 18F-FAPI#18F-FDG
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Atherosclerosis
68Ga-FAPI PET/MR for Atherosclerosis
A thin-cap fibroatheroma with a large necrotic core and macrophage infiltration marks the vulnerable plaque. Fibroblast activating protein (FAP) is an active serine protease, which can degrade type I collagen, potentially…
- Trial name
- NCT05036759
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Gastrointestinal Cancers, Cholangiocarcinoma
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
Prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of [18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, including hepatocellular carcinoma…
- Conditions
- Gastrointestinal Cancers, Cholangiocarcinoma, Gastric Cancer, Colorectal Cancer
- Trial name
- 18F-FAPI-74 GI (NCT05641896)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 6 sites in United States
- Volunteers
- 112 people
- Sponsor
- SOFIE
Metastatic Colorectal Cancer, Metastatic Cancer to Liver
FAPI Molecular Imaging for Diagnosis of the CMS4 Unfavorable Colorectal Cancer Subtype
Colorectal cancer (CRC) is the 3rd most common cancer worldwide and accounts for ~14,000 new diagnoses and ~5,000 deaths in the Netherlands yearly (1.9 million and 935 thousand on a global level).
- Trial name
- FoCus (NCT06191120)
- Testing
- [18F]-ALF-FAPI-74 PET/CT scan
- Where
- Netherlands
- Volunteers
- 45 people
- Sponsor
- UMC Utrecht
Liver Fibrosis, FAP
18F-FAPI PET in the Diagnosis of Liver Fibrosis
It is an open label observation clinical trial, all participants are chronic liver disease. The investigators deem to make a novel evaluate criteria to hepatic fibrosis.
- Conditions
- Liver Fibrosis, FAP, Positron Emission Tomography
- Trial name
- NCT05262647
- Testing
- 18F-FAPI
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Pancreatic Cancer, Cholangiocarcinoma
[68Ga]Ga-FAPI-46 Positron Emission Tomography (PET) Scan to Improve the Imaging of Pancreatic and Bile Duct Cancer
The goal of this clinical trial is to evaluate the clinical use of [68Ga]Ga-FAPI-46 PET (positron emission tomography)/CT (computed tomography) imaging in patients with pancreatic or bile duct cancer.
- Trial name
- PANSCAN-1 (NCT05957250)
- Testing
- [68Ga]Ga-FAPI-46 PET/CT
- Where
- Netherlands
- Volunteers
- 63 people
- Sponsor
- Amsterdam UMC, location VUmc
Crohn Disease
A Non-invasive Diagnostic Model for Intestinal Fibrosis in Crohn's Disease Based on 18F-FAPI PET Imaging
Crohn's disease (CD) is a chronic transmural inflammatory bowel disease. Prolonged episodes of inflammation can lead to intestinal fibrosis, leading to intestinal stenosis and obstruction.
- Trial name
- NCT05824962
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xiao Chen
Lung Cancer
Comparison of 68Ga-FAPI-46 PET and 18F-FDG PET in Lung Cancer
This is a prospective, single-center, single arm, open label study to evaluate the performance of 68Ga-FAPI-46 for the diagnosis of primary and metastatic lesions of lung cancer with comparison to 18F-FDG PET.
- Trial name
- NCT05617742
- Testing
- 68Ga-FAPI-46
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- Chang Gung Memorial Hospital
Crohn Disease
Fibrosis Associated Protein Inhibitor (FAPI) Radiotracer-based Imaging to Identify Fibrotic Intestinal Crohn's Disease
Crohn's Disease (CD) is a chronic inflammatory condition that can affect any part of the intestine and currently has no cure. It affects 6.8 million people worldwide with UK healthcare costs in excess of £1 billion per year.
- Trial name
- FATE-CD (NCT07152431)
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Edinburgh
Prostate Cancer
Evaluation of Fapi-pet in Prostate Cancer.
The investigators explore the biodistribution of FAPI-PET expression in primary high-risk prostate cancer in men undergoing RALP and eLND and in men with metastatic PCa about to start next generation antiandrogen.
- Trial name
- FAPIPETPCA (NCT05192694)
- Testing
- Computed tomography
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Helsinki University Central Hospital
Hepatocellular Carcinoma (HCC)
The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
This study aims to investigate the value of 68Ga-FAPI PET/CT in the efficacy evaluation of advanced unresectable hepatocellular carcinoma patients undergoing systemic antitumor therapy.
- Trial name
- NCT06746194
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Inflammatory Bowel Disease
Characterizing Inflammatory Bowel Disease With 68Ga-FAPI PET/CT
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as inflammatory bowel disease.
- Trial name
- NCT04507932
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Endometriosis, Deep Infiltrating Endometriosis
Prospective Trial of [18F]AlF-FAPI-74 for PET Imaging of Fibroblast Activation Protein in Patients With Endometriosis
The goal of this clinical trial is to learn whether [18F]AlF-FAPI-74 PET/CT can help detect endometriosis in adult women who are already scheduled for laparoscopy due to suspicion of deep infiltrating endometriosis or superficial…
- Conditions
- Endometriosis, Deep Infiltrating Endometriosis, Women, Superficial Peritoneal Endometriosis
- Trial name
- EM-FAPI (NCT07876648)
- Testing
- [18F]AlF-FAPI-74 PET/CT
- Where
- Belgium
- Volunteers
- 64 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Peritoneal Metastasis, FAPI
The Value of 68Ga-FAPI PET/CT for Evaluating Peritoneal Treatment Response
Peritoneal metastases (PM), commonly originating from gastrointestinal and ovarian cancers, are associated with a poor prognosis and limited treatment options due to the diffuse nature of the disease and the inability of systemic…
- Trial name
- INTERACT-FAPI (NCT06957782)
- Testing
- ⁶⁸Ga-FAPI-46
- Volunteers
- 16 people
- Sponsor
- Erasmus Medical Center
Cholangiocarcinoma, Pancreatic Adenocarcinoma
FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers
Pancreatic cancer is one of the worst-prognosed cancers with a 5-year survival rate of less than 10%. Its incidence has been steadily increasing for several years in France and worldwide.
- Trial name
- FAPDIG (NCT07478523)
- Testing
- TEP-TDM au 68Ga-FAPI-46
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Bordeaux
PDAC - Pancreatic Ductal Adenocarcinoma, FAP
Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC.
- Trial name
- FAPI-46 PDAC (NCT05262855)
- Testing
- [68Ga]FAPI-46
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- SOFIE
Positron Emission Tomography, Pancreatic Cancer
Pancreatic Cancer Diagnosis With FAPI-PET Imaging
Staging pancreatic cancer (PC) presents a clinical challenge. Triphasic whole body CT is the primary imaging method in diagnosing, staging and during follow up.
- Conditions
- Positron Emission Tomography, Pancreatic Cancer, FAPI, Diagnostics
- Trial name
- NCT07098598
- Testing
- PET/CT
- Where
- Finland
- Volunteers
- 100 people
- Sponsor
- Turku University Hospital
Malignant Tumor, Positron Emission Tomography
68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer
Adding targeted covalent radiopharmaceutical (TCR) moiety to fibroblast activation protein inhibitor (FAPI) can increase tumor uptake and tumor retention in pre-clinical studies.
- Conditions
- Malignant Tumor, Positron Emission Tomography, Fibroblast Activation Protein Inhibitor
- Trial name
- NCT06084767
- Testing
- 68Ga-TCR-FAPI PET/CT
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Chronic Kidney Disease, Cardiac Magnetic Resonance
Multimodal Imaging Assessment of Chronic Kidney Disease Patients at Different Stages From a Cardio-Renal Interaction Perspective
This study is a prospective cohort investigation in which consecutive eligible patients undergo 18F-FAPI PET/MR imaging. Chronic kidney disease (CKD) participants are stratified into two groups:Group I ：CKD stages 1-3（eGFR ≥ 30…
- Conditions
- Chronic Kidney Disease, Cardiac Magnetic Resonance, 18F-FAPI
- Trial name
- NCT07107919
- Testing
- 18F PET/MR
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The Affiliated Hospital of Qingdao University